FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2139898001> ?p ?o ?g. }

• W2139898001 abstract "Abstract Background Gemcitabine, a deoxycytidine nucleoside analog, is the current standard chemotherapy used as first-line treatment for patients with locally advanced or metastatic cancer of the pancreas, and extends life survival by 5.7 months. Advanced pancreatic cancer thus remains a highly unmet medical need and new therapeutic agents are required for this patient population. Troxacitabine (Troxatyl™) is the first unnatural L-nucleoside analog to show potent preclinical antitumor activity and is currently under clinical investigation. Troxacitabine was recently evaluated as a first-line therapy in 54 patients with advanced adenocarcinoma of the pancreas and gave comparable overall results to those reported with gemcitabine in recently published randomized trials. Methods The human pancreatic adenocarcinoma cell lines, AsPC-1, Capan-2, MIA PaCa-2 and Panc-1, were exposed to troxacitabine or gemcitabine alone or in combination, for 72 h, and the effects on cell growth were determined by electronic particle counting. Synergistic efficacy was determined by the isobologram and combination-index methods of Chou and Talalay. Mechanistic studies addressed incorporation of troxacitabine into DNA and intracellular levels of troxacitabine and gemcitabine metabolites. For in vivo studies, we evaluated the effect of both drugs, alone and in combination, on the growth of established human pancreatic (AsPC-1) tumors implanted subcutaneously in nude mice. Statistical analysis was calculated by a one-way ANOVA with Dunnett as a post-test and the two-tailed unpaired t test using GraphPad prism software. Results Synergy, evaluated using the CalcuSyn Software, was observed in all four cell-lines at multiple drug concentrations resulting in combination indices under 0.7 at Fa of 0.5 (50% reduction of cell growth). The effects of drug exposures on troxacitabine and gemcitabine nucleotide pools were analyzed, and although gemcitabine reduced phosphorylation of troxacitabine when cells were exposed at equal drug concentrations, there was no effect on phosphorylated pools at drug combinations that were synergistic. The amount of troxacitabine incorporated into DNA was also not affected by the presence of gemcitabine. In vivo testing against a human pancreatic (AsPC-1) xenograft mouse tumor model indicated that both drugs were more than additive at well-tolerated doses and schedule. The biological basis for this synergy is unclear as we did not observe changes in apoptosis, DNA repair, troxacitabine incorporation into DNA or troxacitabine metabolism in the presence of gemcitabine. Conclusion These data, together with phase I clinical data showing tolerability of both agents when combined, suggest combination therapy with troxacitabine and gemcitabine warrants further evaluation in advanced pancreatic cancer patients." @default.
• W2139898001 created "2016-06-24" @default.
• W2139898001 creator A5008803823 @default.
• W2139898001 creator A5017848401 @default.
• W2139898001 creator A5030147093 @default.
• W2139898001 creator A5032920417 @default.
• W2139898001 creator A5041161792 @default.
• W2139898001 creator A5045280265 @default.
• W2139898001 creator A5063063379 @default.
• W2139898001 creator A5065941460 @default.
• W2139898001 creator A5086824287 @default.
• W2139898001 date "2007-07-03" @default.
• W2139898001 modified "2023-10-17" @default.
• W2139898001 title "Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer" @default.
• W2139898001 cites W1491166067 @default.
• W2139898001 cites W1501769303 @default.
• W2139898001 cites W1558518646 @default.
• W2139898001 cites W1571638899 @default.
• W2139898001 cites W1931508686 @default.
• W2139898001 cites W1936026926 @default.
• W2139898001 cites W1939358691 @default.
• W2139898001 cites W1967805052 @default.
• W2139898001 cites W1977206788 @default.
• W2139898001 cites W1992252639 @default.
• W2139898001 cites W2017342479 @default.
• W2139898001 cites W2017471791 @default.
• W2139898001 cites W2022389416 @default.
• W2139898001 cites W2024382021 @default.
• W2139898001 cites W2032707644 @default.
• W2139898001 cites W2037901246 @default.
• W2139898001 cites W2039119371 @default.
• W2139898001 cites W2050286670 @default.
• W2139898001 cites W2060765563 @default.
• W2139898001 cites W2073746430 @default.
• W2139898001 cites W2074712302 @default.
• W2139898001 cites W2077945404 @default.
• W2139898001 cites W2085027216 @default.
• W2139898001 cites W2100304874 @default.
• W2139898001 cites W2116456988 @default.
• W2139898001 cites W2139318317 @default.
• W2139898001 cites W2139407325 @default.
• W2139898001 cites W2142408819 @default.
• W2139898001 cites W2270686918 @default.
• W2139898001 cites W4231031590 @default.
• W2139898001 cites W4301038403 @default.
• W2139898001 doi "https://doi.org/10.1186/1471-2407-7-121" @default.
• W2139898001 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1948004" @default.
• W2139898001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17608948" @default.
• W2139898001 hasPublicationYear "2007" @default.
• W2139898001 type Work @default.
• W2139898001 sameAs 2139898001 @default.
• W2139898001 citedByCount "25" @default.
• W2139898001 countsByYear W21398980012012 @default.
• W2139898001 countsByYear W21398980012013 @default.
• W2139898001 countsByYear W21398980012014 @default.
• W2139898001 countsByYear W21398980012015 @default.
• W2139898001 countsByYear W21398980012016 @default.
• W2139898001 countsByYear W21398980012017 @default.
• W2139898001 countsByYear W21398980012019 @default.
• W2139898001 countsByYear W21398980012021 @default.
• W2139898001 countsByYear W21398980012022 @default.
• W2139898001 crossrefType "journal-article" @default.
• W2139898001 hasAuthorship W2139898001A5008803823 @default.
• W2139898001 hasAuthorship W2139898001A5017848401 @default.
• W2139898001 hasAuthorship W2139898001A5030147093 @default.
• W2139898001 hasAuthorship W2139898001A5032920417 @default.
• W2139898001 hasAuthorship W2139898001A5041161792 @default.
• W2139898001 hasAuthorship W2139898001A5045280265 @default.
• W2139898001 hasAuthorship W2139898001A5063063379 @default.
• W2139898001 hasAuthorship W2139898001A5065941460 @default.
• W2139898001 hasAuthorship W2139898001A5086824287 @default.
• W2139898001 hasBestOaLocation W21398980011 @default.
• W2139898001 hasConcept C121608353 @default.
• W2139898001 hasConcept C126322002 @default.
• W2139898001 hasConcept C143998085 @default.
• W2139898001 hasConcept C185592680 @default.
• W2139898001 hasConcept C2776543447 @default.
• W2139898001 hasConcept C2777333352 @default.
• W2139898001 hasConcept C2780210213 @default.
• W2139898001 hasConcept C2780258809 @default.
• W2139898001 hasConcept C2908647359 @default.
• W2139898001 hasConcept C71240020 @default.
• W2139898001 hasConcept C71924100 @default.
• W2139898001 hasConcept C98274493 @default.
• W2139898001 hasConcept C99454951 @default.
• W2139898001 hasConceptScore W2139898001C121608353 @default.
• W2139898001 hasConceptScore W2139898001C126322002 @default.
• W2139898001 hasConceptScore W2139898001C143998085 @default.
• W2139898001 hasConceptScore W2139898001C185592680 @default.
• W2139898001 hasConceptScore W2139898001C2776543447 @default.
• W2139898001 hasConceptScore W2139898001C2777333352 @default.
• W2139898001 hasConceptScore W2139898001C2780210213 @default.
• W2139898001 hasConceptScore W2139898001C2780258809 @default.
• W2139898001 hasConceptScore W2139898001C2908647359 @default.
• W2139898001 hasConceptScore W2139898001C71240020 @default.
• W2139898001 hasConceptScore W2139898001C71924100 @default.
• W2139898001 hasConceptScore W2139898001C98274493 @default.
• W2139898001 hasConceptScore W2139898001C99454951 @default.
• W2139898001 hasIssue "1" @default.
• W2139898001 hasLocation W21398980011 @default.

• next